Table 3.

HRs for mortality or disease recurrence by presence of anti-HPV antibodies

Antibodies/tumor DNAOverall mortality, HR (95% CI)Disease-specific mortality, HR (95% CI)Disease recurrence, HR (95% CI)
HPV-16 VLP0.4 (0.2-0.8)0.4 (0.1-0.9)0.6 (0.2-1.5)*
HPV-16 E60.1 (0.04-0.5)0.1 (0.02-0.5)0.3 (0.1-1.5)
HPV-16 E70.4 (0.1-0.9)0.3 (0.1-0.9)0.2 (0.02-1.4)
HPV-16 E6 and/or E70.3 (0.1-0.7)0.3 (0.1-0.9)0.5 (0.1-1.7)*
HPV-16 E6 and E70.2 (0.1-0.6)0.1 (0.03-0.7)
HPV DNA+0.2 (0.1-0.6)0.2 (0.1-0.7)0.6 (0.2-2.0)*
  • NOTE: HRs adjusted for age, gender, stage of disease, tumor grade, histology, surgery, and radiation; reference group includes those negative for the HPV antibody examined.

  • * P > 0.20.

  • P ≥ 0.10.

  • HR not estimable due to 0 recurrences among patients with anti–HPV-16 E6 and E7 antibodies present.